Drug intelligence / Profile preview

erlotinib + rosuvastatin

Development stage: Phase 1
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer and pancreatic cancer. It works by blocking the EGFR, which is involved in cancer cell growth. Rosuvastatin is a statin that inhibits HMG-CoA reductase, an enzyme crucial for cholesterol synthesis. It is used to lower cholesterol levels and reduce the risk of cardiovascular diseases. The combination of erlotinib and rosuvastatin has been explored in clinical trials for synergistic effects in cancer treatment, though it is not a standard combination for cancer therapy.

Brand names: Tarceva (erlotinib)Crestor (rosuvastatin)Ezallor Sprinkle (rosuvastatin)

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on erlotinib + rosuvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + rosuvastatin.